AstraZeneca: promising results in gastric cancer
(CercleFinance.com) - AstraZeneca announced on Friday that a combination of its monoclonal antibody Imfinzi and chemotherapy had shown positive Phase III results in the treatment of gastric cancer.
According to the company, this combination resulted in a statistically significant and clinically relevant improvement in event-free survival, i.e. the absence of relapse, in the treatment of cancers of the stomach and gastro-oesophageal junction.
With nearly a million new cases diagnosed each year, gastric cancer is the fifth most common cancer worldwide.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
According to the company, this combination resulted in a statistically significant and clinically relevant improvement in event-free survival, i.e. the absence of relapse, in the treatment of cancers of the stomach and gastro-oesophageal junction.
With nearly a million new cases diagnosed each year, gastric cancer is the fifth most common cancer worldwide.
Copyright (c) 2025 CercleFinance.com. All rights reserved.